NASDAQ: ALGSAligos Therapeutics Inc Stock
$28.67+0.70 (+2.5%)
Updated Dec 6, 2024
ALGS Price
$28.67
Fair Value Price
$1.43
Market Cap
$102.86M
52 Week Low
$6.76
52 Week High
$30.43
P/E
-3.92x
P/B
2.05x
P/S
9.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.00M
Earnings
-$76.95M
Gross Margin
100%
Operating Margin
-1,577.26%
Profit Margin
-1,283.2%
Debt to Equity
0.77
Operating Cash Flow
-$85M
Beta
1.04
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALGS Overview
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics to address unmet medical needs in viral and liver diseases. Aligos uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. Its lead drug candidates are ALG-010133, ALG-000184, ALG-020572, ALG-055009, as well as siRNA -based candidates, ALG-125755, ALG-125097, ALG-125819. Aligos was incorporated in 2018 and is headquartered in South San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALGS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
B
Growth
C
Momentum
D
Sentiment
C
Safety
D
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ALGS
Ranked#296 of 554
Ranked#296 of 554
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $25.45 | A | |
| $6.72 | A | |
| $19.82 | A |
Be the first to know about important ALGS news, forecast changes, insider trades & much more!
ALGS News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALGS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALGS ($28.67) is overvalued by 1,899.99% relative to our estimate of its Fair Value price of $1.43 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALGS ($28.67) is not significantly undervalued (1,899.99%) relative to our estimate of its Fair Value price of $1.43 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALGS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALGS due diligence checks available for Premium users.
Valuation
ALGS fair value
Fair Value of ALGS stock based on Discounted Cash Flow (DCF)
Price
$28.67
Fair Value
$1.43
Overvalued by
1,899.99%
ALGS ($28.67) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALGS ($28.67) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALGS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALGS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.92x
Industry
-105.55x
Market
29.86x
ALGS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.05x
Industry
5.68x
ALGS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALGS's financial health
Profit margin
Revenue
$1.3M
Net Income
-$19.3M
Profit Margin
-1,517.7%
ALGS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ALGS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$88.4M
Liabilities
$38.3M
Debt to equity
0.77
ALGS's short-term assets ($79.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALGS's short-term assets ($79.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALGS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.1M
Investing
$10.4M
Financing
-$4.0k
ALGS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALGS vs Biotech Stocks
Aligos Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.